Volume 85 Issue 10 | p. 29 | Concentrates
Issue Date: March 5, 2007

Bristol-Myers Squibb Allies With Adnexus

Department: Business

Bristol-Myers Squibb and Adnexus Therapeutics will work together to discover and develop protein-based oncology therapies. Adnexus will apply its PROfusion protein design technology in up to six research programs to identify drug candidates. Called adnectins, these candidates will be culled from a proprietary protein class based on fibronectin, an extracellular protein abundant in human serum. BMS will provide $30 million in upfront fees and research funding over the next three years and be responsible for development and commercialization.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment